Although BCR-ABL fusion oncoprotein tyrosine kinase inhibitors (BCR-ABL TKIs) can substantially improve the survival rate of chronic myeloid leukemia (CML), they are clinically accompanied by severe hepatotoxicity. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.